- Home
- UTHR vs CYBR Comparison
UTHR vs CYBR Comparison
Compare UTHR & CYBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- CYBR
- Stock Information
- Founded
- UTHR 1996
- CYBR 1999
- Country
- UTHR United States
- CYBR Israel
- Employees
- UTHR N/A
- CYBR N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- CYBR Computer Software: Prepackaged Software
- Sector
- UTHR Health Care
- CYBR Technology
- Exchange
- UTHR Nasdaq
- CYBR Nasdaq
- Market Cap
- UTHR 14.4B
- CYBR 15.5B
- IPO Year
- UTHR 1999
- CYBR 2014
- Fundamental
- Price
- UTHR $308.00
- CYBR $364.46
- Analyst Decision
- UTHR Buy
- CYBR Strong Buy
- Analyst Count
- UTHR 12
- CYBR 33
- Target Price
- UTHR $392.00
- CYBR $406.21
- AVG Volume (30 Days)
- UTHR 439.7K
- CYBR 562.1K
- Earning Date
- UTHR 04-30-2025
- CYBR 05-13-2025
- Dividend Yield
- UTHR N/A
- CYBR N/A
- EPS Growth
- UTHR 18.86
- CYBR N/A
- EPS
- UTHR 25.10
- CYBR N/A
- Revenue
- UTHR $2,994,100,000.00
- CYBR $1,000,742,000.00
- Revenue This Year
- UTHR $11.45
- CYBR $34.10
- Revenue Next Year
- UTHR $6.11
- CYBR $19.75
- P/E Ratio
- UTHR $12.27
- CYBR N/A
- Revenue Growth
- UTHR 19.84
- CYBR 33.10
- 52 Week Low
- UTHR $260.41
- CYBR $223.41
- 52 Week High
- UTHR $417.82
- CYBR $421.00
- Technical
- Relative Strength Index (RSI)
- UTHR 57.25
- CYBR 60.42
- Support Level
- UTHR $290.02
- CYBR $355.00
- Resistance Level
- UTHR $319.40
- CYBR $369.30
- Average True Range (ATR)
- UTHR 10.02
- CYBR 10.92
- MACD
- UTHR 2.72
- CYBR 3.12
- Stochastic Oscillator
- UTHR 69.99
- CYBR 92.09
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About CYBR CyberArk Software Ltd.
CyberArk is a cybersecurity vendor focused on the identity market. The company's core privileged access management offering is a market leader in that subsegment, with more than half of the Fortune 500 as CyberArk customers. The identity security vendor was founded in 1999 and has around 9,000 customers across various industries. While CyberArk historically sold its security solutions primarily via on-premises licenses, over the past few years it has transitioned to a subscription recurring-revenue model.